Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
Financial Results for the year Ended December 31, 2023
截至2023年12月31日止年度的财务业绩
As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million. The Company believes that its existing cash resources will be sufficient to meet its projected operating requirements through the second quarter of 2025, which includes the capital required to fund our ongoing operations, including R&D, the completion of the Phase 1 PK study related to our new generation platform and the GLP-2/OXM collaborative research we are conducting with OPKO.
截至2023年12月31日，Entera的现金及现金等价物为1,100万美元。该公司认为，其现有现金资源将足以满足其到2025年第二季度的预计运营需求，其中包括为我们的持续业务提供资金所需的资金，包括研发、与我们的新一代平台相关的第一阶段PK研究的完成以及我们与OPKO进行的GLP-2/OXM合作研究。
Research and development expenses for the year ended December 31, 2023 were $4.5 million, as compared to $5.8 million for the year ended December 31, 2022. The decrease of $1.3 million was primarily due to a decrease of $1.5 million in pre-clinical activity and materials costs and a decrease of $0.6 million in employee compensation, including a one-time payment made to a former employee pursuant to the terms of his separation agreement. The decrease was partially offset by an increase of $0.8 million in clinical expenses for our Phase 1 PK study related to our new generation platform and new formulations for EB612.
截至2023年12月31日止年度的研发费用为450万美元，而截至2022年12月31日的年度为580万美元。减少130万美元的主要原因是临床前活动和材料成本减少了150万美元，员工薪酬减少了60万美元，包括根据离职协议条款向一名前雇员支付的一次性付款。与我们的新一代平台和 EB612 新配方有关的 1 期 PK 研究的临床费用增加了 80 万美元，部分抵消了这一下降。
General and administrative expenses for the year ended December 31, 2023 were $4.4 million, compared to $7.3 million for the year ended December 31, 2022. The decrease of $2.8 million was mainly attributable to a decrease of $1.1 million in employee compensation, including a one-time payment to our former employee pursuant to the terms of his separation agreement, a decrease of $0.8 million as part of a restructuring of professional fees and other advisor expenses, a decrease in Board fees of $0.2 million due to the Board's forfeiture of their fees for the third and fourth quarters of 2023 and a decrease of $0.7 million in D&O insurance costs.
截至2023年12月31日止年度的一般和管理费用为440万美元，而截至2022年12月31日的年度为730万美元。减少280万美元的主要原因是员工薪酬减少了110万美元，其中包括根据我们的前雇员离职协议条款向其一次性付款，专业费用和其他顾问费用重组的一部分减少了80万美元，由于董事会没收了2023年第三和第四季度的费用，董事会费用减少了20万美元，D&D减少了70万美元 O 保险费用。
Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.
截至2023年12月31日止年度的运营支出为890万美元，而截至2022年12月31日的年度为1,300万美元。
Net loss was $8.9 million, or $0.31 per ordinary share (basic and diluted), for the year ended December 31, 2023, as compared to $13.1 million, or $0.45 per ordinary share (basic and diluted), for the year ended December 31, 2022.
截至2023年12月31日止年度的净亏损为890万美元，合每股普通股（基本和摊薄后）0.31美元，而截至2022年12月31日止年度的净亏损为1,310万美元，合每股普通股（基本和摊薄后）0.45美元。
译文内容由第三方软件翻译。